Dysregulation of UTX has been implicated to be involved in several cancers including renal cell carcinoma and multiple myeloma, as loss or mutation of UTX can lead to aberrant gene silencing and tumorigenesis [77]. This evidence concerns the gene KDM6A and plasma cell myeloma.